Yes—a group of House Democrats, led by Rep. Judy Chu with Reps. Kathy Castor, Summer Lee, and Chris Pappas, introduced the **Drug Deal Disclosure Act** to force the Trump Administration to release the terms of its prescription-drug pricing deals with manufacturers.
The bill would require the government to publish the agreements it struck privately with 14 of the country's largest drugmakers, according to Rep. Summer Lee's office. A "covert" or secret agreement here means a deal whose full text, concessions, and savings math the public has not seen. Lawmakers say the administration announced results but withheld the fine print, so no one can verify who benefits.
Table of Contents
- What the Drug Deal Disclosure Act would require
- What deals are lawmakers asking about?
- What the companies got in return
- Are the advertised savings real?
- What happens next and what you can do
- Frequently Asked Questions
What the Drug Deal Disclosure Act would require
The bill targets transparency, not the drug prices themselves. It would compel the Department of Health and Human Services (HHS)—the federal agency that runs Medicare and Medicaid—to publicly release the documentation behind each pricing deal.
A parallel Senate version arrived on April 21–22, 2026, introduced by Finance Committee Ranking Member Ron Wyden alongside 18 Senate Democrats. That bill also directs the Congressional Budget Office and Government Accountability Office to analyze the deals' economic and budgetary impact, according to the Senate Finance Committee. In short, one bill forces disclosure of the paperwork; the companion measures ask independent scorekeepers to tell Congress what the deals actually cost or save.
What deals are lawmakers asking about?
On December 19, 2025, President trump announced that 14 of the 17 largest drugmakers had signed "Most Favored Nation" (MFN) pricing agreements. MFN pricing means U.S. buyers pay no more than the lowest price the company charges in other wealthy nations.
The signatories, per the White House fact sheet, include Pfizer, AstraZeneca, EMD Serono, Novo Nordisk, Eli Lilly, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi. The push began July 31, 2025, when Trump sent letters to manufacturers demanding MFN pricing. The deals apply the matched prices to Medicaid and cash-paying buyers through a new TrumpRx.gov portal.
What the companies got in return
The agreements were not one-sided. In exchange for lower listed prices, companies received a three-year suspension of potential pharmaceutical tariffs, paired with roughly $150 billion in promised U.S. investment, according to the White House and CNN.
Wyden's accompanying report argues the terms tilt toward industry. It describes tax breaks, regulatory relief, and exemptions from Trump's other drug-pricing efforts as part of the trade, per the Senate Finance report. That trade-off is the heart of the dispute. Lawmakers want to know whether the concessions given away outweigh the savings patients actually receive.
Are the advertised savings real?
The administration published specific price cuts. Merck's diabetes drug Januvia would drop to $100 from $330; Gilead's hepatitis C drug Epclusa to $2,425 from $24,920; and GSK's Advair Diskus 500/50 to $89 from $265.
But those are announced figures, not verified outcomes. Independent reporting found that some signatory drugmakers raised list prices after signing, which muddies the claim of patient benefit, according to Drug Discovery Trends. Key limits a reader should keep in mind:.
- The full deal terms, concessions, and proof of real savings remain undisclosed.
- "Cash-paying" and Medicaid prices may not reach people with commercial insurance.
- A lower list price can be offset by separate increases elsewhere in a company's catalog.
What happens next and what you can do
Both bills are newly introduced—not passed. Introduction is only the first step; a bill must clear committees and both chambers before it can become law, and no vote is guaranteed.
There is no FDA approval or clinical action involved here. This is pricing and transparency policy, so nothing about drug safety or availability changes because of these bills. To follow the issue directly:.
- Read the primary Drug Deal Disclosure Act accompanying report for the lawmakers' full argument.
- Check TrumpRx.gov listings against your pharmacy's actual price before assuming a discount applies.
- Contact your own House member and senators if you want to weigh in while the bills are pending.
Frequently Asked Questions
Who introduced the Drug Deal Disclosure Act?
Reps. Judy Chu, Kathy Castor, Summer Lee, and Chris Pappas introduced the House bill, with Sen. Ron Wyden and 18 Democrats introducing the Senate companion.
Does the bill lower drug prices itself?
No. It forces disclosure of the existing agreements and orders independent analysis; it does not set or change prices.
What is "Most Favored Nation" pricing?
It requires U.S. buyers to pay no more than the lowest price a drugmaker charges in other developed countries, applied here to Medicaid and cash buyers.